Zoetis (ZTS) Expected to Release Earnings on Thursday

Zoetis (NYSE:ZTS) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of $1.85 per share and revenue of $2.5015 billion for the quarter. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business’s revenue was up 2.9% compared to the same quarter last year. During the same period last year, the company earned $1.48 earnings per share. On average, analysts expect Zoetis to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Zoetis Stock Down 1.3%

Shares of NYSE ZTS opened at $76.08 on Wednesday. The stock has a market cap of $31.90 billion, a P/E ratio of 12.62, a P/E/G ratio of 1.20 and a beta of 0.74. The firm has a 50 day moving average price of $76.88 and a 200 day moving average price of $101.64. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis has a 52-week low of $71.47 and a 52-week high of $160.48.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.8%. Zoetis’s payout ratio is 35.16%.

Analyst Ratings Changes

A number of research firms recently commented on ZTS. Stifel Nicolaus lowered their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research report on Friday, June 26th. HSBC reduced their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Argus restated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Citigroup dropped their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, UBS Group cut their price objective on Zoetis from $99.00 to $85.00 and set a “neutral” rating on the stock in a report on Monday, July 27th. Eight analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $118.33.

Insider Buying and Selling

In other news, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the acquisition, the director owned 27,862 shares in the company, valued at approximately $2,114,168.56. This represents a 7.73% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 11,650 shares of company stock worth $886,384 over the last ninety days. Company insiders own 0.22% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ZTS. Prosperity Bancshares Inc acquired a new stake in Zoetis in the 4th quarter valued at approximately $25,000. Intesa Sanpaolo Wealth Management acquired a new position in Zoetis during the 4th quarter worth approximately $42,000. DV Equities LLC bought a new position in shares of Zoetis during the 4th quarter worth approximately $77,000. Bellevue Group AG grew its stake in shares of Zoetis by 32.7% during the 3rd quarter. Bellevue Group AG now owns 872 shares of the company’s stock worth $128,000 after acquiring an additional 215 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. raised its holdings in shares of Zoetis by 23.7% in the third quarter. Newbridge Financial Services Group Inc. now owns 1,145 shares of the company’s stock valued at $168,000 after purchasing an additional 219 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.